Notice: Undefined index: HTTP_ACCEPT_LANGUAGE in C:\inetpub\wwwroot\technology_detail.php on line 331
 Technology Detail


The Office of Technology Licensing was established in 1970 to transfer technologies developed at Stanford. Find out more about OTL's history, mission, staff, and statistics.

Login to TechFinder » 

Detection of Protein Modification


Stanford Reference:

02-123


Abstract


This invention is a broadly applicable biosensor platform for detecting protein-protein interactions in eukaryotic and mammalian cells in situ or in vitro. This system uses small beta-lactamase fragments to perform assays on molecules, irrespective of their localization within the cell. In addition, detection with a fluorescent cell-permeable substrate provides a low-background signal. The technology can be used for diagnostics as well as other applications.

Related Technologies
The Blau lab has developed several inventions that can be used for detecting molecular interactions in mammalian cells. These technologies are described in the following dockets:
    S96-125 - “Novel System for Detection of Protein-protein Interactions in Mammalian Cells”
    S06-318 – “GPCR Functional Assay”
    S07-028 – “Detection of Molecular Interactions Using Reduced Affinity Enzyme Complementation Reporter System”

Available Fields of Use
This technology is available for licensing in the field of diagnostics or for use in whole living organisms. It is not available for the fields of research reagents or drug discovery.

Applications


  • Detection - study of constitutive and inducible protein-protein interactions

Advantages


  • Small, monomeric molecule - beta-lactamase fragments are unlikely to alter the structure of chimeric proteins
  • Fast, easy detection:
    • signal within minutes
    • low background
    • fluorescent, cell-permeable substrate
  • Study compartmentalized proteins - can assay dimerization of fragments irrespective of protein localization

Publications



Related Web Links



Innovators & Portfolio



Patent Status



Date Released

 6/14/2011
 

Licensing Contact


Katharine Ku, Director
(650) 723-0651 (Business)
Login to Request Information

[-] Map/Timeline

95-040 Green Fluorescent Protein (GFP) Mutants
02-096 Method to Determine the Risk for Side Effects of an SSRI Treatment (5HT2a)
02-179 Diagnosis of CML and other leukemias using beta-catenin biomarker

more technologies »

Related Keywords


reporter gene   protein-protein interactions   diagnostic: detection   microbial detection   Pathogen Detection   beta-lactamase   complementation   
 

   

  

Also of Interest...
95-040 Green Fluorescent Protein (GFP) Mutants
02-096 Method to Determine the Risk for Side Effects of an SSRI Treatment (5HT2a)
02-179 Diagnosis of CML and other leukemias using beta-catenin biomarker

Recently Viewed...
S02-123 Detection of Protein Modification